Division of Pediatric Allergy and Immunology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkey.
Pediatr Allergy Immunol. 2021 Nov;32(8):1781-1787. doi: 10.1111/pai.13588. Epub 2021 Jul 16.
Clarithromycin hypersensitivity is reported as the most common cause of non-β-lactam antibiotic allergy in children. Clarithromycin is frequently prescribed in cases of suspected β-lactam hypersensitivity. Oral provocation tests stand as the gold standard to confirm drug hypersensitivity as diagnostic value of skin tests is variable. We analyzed the frequency of true clarithromycin hypersensitivity ratio and its relationship with β-lactam allergy among children with suspected clarithromycin hypersensitivity and evaluated the diagnostic value of skin tests.
The study included 160 children referred with suspected clarithromycin hypersensitivity. Clinical history and allergy workups including skin tests or/and oral provocation tests were retrieved from medical records.
Oral provocation test confirmed clarithromycin hypersensitivity rate was 5.6% (n = 9/160). Skin tests with clarithromycin showed positivity in 32.6% (n = 29/89) of the tested patients. The sensitivity of clarithromycin skin tests was negligible, and specificity was 73.9% (95% confidence interval [CI], 64.7-81.8). Eighty-eight of the patients (55%) reported that they had previously tolerated a β-lactam antibiotic. β-lactam hypersensitivity was suspected in 40% (n = 64/160) of the patients (simultaneous [n = 10], sequential [n = 19], distant form [n = 35]) in relation with clarithromycin usage. β-lactam hypersensitivity (95% CI, 2.1-70.6, p = .005) and sequential usage of clarithromycin after the development of a rash with amoxicillin-clavulanic acid (95% CI, 2.0-96.4, p = .007) were found as risk factors for confirmed clarithromycin hypersensitivity.
The frequency of confirmed clarithromycin hypersensitivity was found low among suspected patients. Oral provocation test is crucial for definite diagnosis. Confirmed β-lactam allergy may be attributed as a risk factor for clarithromycin hypersensitivity, particularly clarithromycin treatment after a developing rash with amoxicillin-clavulanic acid in sequential usage.
克拉霉素过敏反应被报道为儿童中最常见的非β-内酰胺类抗生素过敏反应原因。在疑似β-内酰胺过敏反应的情况下,常开克拉霉素处方。口服激发试验是确认药物过敏反应的金标准,因为皮肤试验的诊断价值是可变的。我们分析了疑似克拉霉素过敏反应儿童中真正克拉霉素过敏反应的频率及其与β-内酰胺过敏反应的关系,并评估了皮肤试验的诊断价值。
该研究纳入了 160 名因疑似克拉霉素过敏反应而就诊的儿童。从病历中检索了临床病史和过敏检查,包括皮肤试验或/和口服激发试验。
口服激发试验证实克拉霉素过敏反应率为 5.6%(n=160)。对 89 名接受克拉霉素皮肤试验的患者中,32.6%(n=29)的皮肤试验结果呈阳性。克拉霉素皮肤试验的敏感性可以忽略不计,特异性为 73.9%(95%置信区间[CI],64.7-81.8)。88 名患者(55%)报告称他们曾耐受过一种β-内酰胺类抗生素。40%(n=160)的患者(同时[n=10]、序贯[n=19]、远隔型[n=35])疑似β-内酰胺过敏反应与克拉霉素使用有关。β-内酰胺过敏反应(95%CI,2.1-70.6,p=0.005)和在阿莫西林-克拉维酸出现皮疹后序贯使用克拉霉素(95%CI,2.0-96.4,p=0.007)被发现是确认克拉霉素过敏反应的危险因素。
疑似患者中确认的克拉霉素过敏反应频率较低。口服激发试验对于明确诊断至关重要。已确认的β-内酰胺过敏反应可能是克拉霉素过敏反应的危险因素,特别是在阿莫西林-克拉维酸出现皮疹后序贯使用克拉霉素时。